Shore Capital Partners Expands Medical Device Portfolio with C2Dx Partnership and Cook Medical Acquisition

Shore Capital Partners, a leading private equity firm, has announced its partnership with C2Dx, a medical device company based in Kalamazoo, Michigan. In addition to this exciting collaboration, Shore Capital and C2Dx have also acquired the Otolaryngology/Head and Neck Surgery (OHNS) family of products from Cook Medical. These products offer minimally invasive procedures for ENT surgeons, enhancing the treatment of various conditions.

The partnership between Shore Capital Partners and C2Dx is set to create an even stronger presence in the medical device industry. Don Pierce, Partner at Shore and Chairman of the Board of C2Dx, expressed his enthusiasm about the collaboration, stating, "We are well-positioned to build on their reputation as an industry leader through both acquisitions and organic growth, and the initial acquisition from Cook Medical complements and differentiates the platform's product offerings."

C2Dx, founded in 2019 by CEO Kevin McLeod and Ann Arbor-based growth capital firm Plymouth Growth Partners, has quickly established itself as a prominent player in the medical device market. With a team of seasoned industry experts and a commitment to growth, C2Dx has expanded its product offerings and capabilities through strategic acquisitions and a focus on customer satisfaction. Their partnership with Shore Capital Partners will enable them to further invest in their team, capabilities, and offerings, ensuring accelerated growth and continued excellence in service and products.

The acquisition of Cook Medical's OHNS product family marks a transformative moment for C2Dx. By leveraging their experienced sales organization, international distributor network, and commitment to product enhancement, C2Dx aims to increase the market penetration of these high-quality ENT and head & neck focused solutions. This acquisition adds to their already impressive portfolio, which includes the Shaw Scalpel, STIC Intra-Compartmental Pressure Monitor, and T/Pump Localized Temperature Therapy System.

Shore Capital Partners and C2Dx are now actively seeking opportunities to strengthen their position as a diversified medical device company. Their focus includes forming new industry partnerships, pursuing business development initiatives, and investing further in their products and team. With a vision to serve multiple specialties and procedures both in the U.S. and internationally, the partnership is poised for significant growth and success.

To learn more about C2Dx and their partnerships, interested parties can visit their website or contact Kevin McLeod or AJ Gauthier for further information.

About Shore Capital Partners

Based in Chicago, Shore Capital Partners is a private equity firm that specializes in microcap investments in various industries, including healthcare, food and beverage, business services, industrial, and real estate. They provide support to management partners, enabling them to grow faster with less risk through access to capital, operational resources, networking opportunities, and shared learnings. With a portfolio of successful private companies, Shore Capital focuses on consolidation and organic growth to generate value for shareholders.

About C2Dx

C2Dx, headquartered in Kalamazoo, Michigan, is a medical device company that invests in niche products to enhance their growth and accessibility globally. With a commitment to providing superior customer service and leading medical products, C2Dx continuously evolves to meet the needs of healthcare providers. Supported by Shore Capital, C2Dx benefits from the expertise of a World-Class Board of Directors with deep experience in the medical device space, operations, and private equity.

In conclusion, the partnership between Shore Capital Partners and C2Dx, along with the acquisition of Cook Medical's OHNS product family, marks a significant milestone for both companies. With a shared vision for growth and excellence, they are poised to make a lasting impact in the medical device industry.